ArticleEClinicalMedicine2025
Prevalence of ocular and visual abnormalities following symptomatic and asymptomatic congenital CMV infection: a systematic review and meta-analysis.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Cytomegalovirus (CMV), the most common congenitally acquired infection, can result in visual disability in affected children. We aimed to estimate the burden of eye and vision disorders amongst children with symptomatic and asymptomatic congenital cytomegalovirus infection (cCMV), to inform the development of guidance for the provision of care. Methods: In this systematic review and meta-analysis, we searched PubMed, Embase, and CINAHL databases up to 6th Feb 2025 for studies reporting ocular disorders or visual impairment (VI) outcomes following cCMV diagnosis. We included longitudinal or cross-sectional studies which reported the frequency of visual or ophthalmic outcomes following an initial diagnosis of symptomatic or asymptomatic cCMV. Summary data, and individual patient level data where available, on the proportions of children noted to have visual impairment or ophthalmic disorders and the manifestation of these disorders, were extracted from published reports. Pooled prevalence of eye and vision outcomes were estimated through random effects models computed using Restricted Maximum Likelihood (REML) estimation. We included studies at lower risk of bias (assessed using the Joanna Briggs Institute tool) in meta-analyses of prevalence (random-effect models) and undertook subgroup analyses. The review protocol was registered with PROSPERO, CRD42021284678. Findings: We identified 4488 articles of which 28 were eligible for inclusion. Of these, 15 studies (total 858 children with symptomatic, 1176 with asymptomatic cCMV) were eligible for meta-analyses. Median follow up time from diagnosis of cCMV ranged from 6 to 156 months. Estimated pooled prevalence in symptomatic cCMV of visual impairment (VI) and ocular disorders 9% (95% CI, 5-14%, Interpretation: Visual disability in cCMV is a strong marker of the broader neurological insult. Ocular disorders are prevalent in symptomatic disease, with consequent need for ongoing ophthalmic care. The low prevalence of sight-impactful disorders in asymptomatic disease suggests little benefit for ongoing ophthalmic surveillance, particularly in health settings with established programmes for whole population childhood eye and vision screening. This review is limited by the absence of information on the timing of diagnosis of the eye and vision disorders, data which would support the development of timeline pathways for ophthalmic surveillance. Funding: Wellcome Trust, National Institute for Health and Care Research (NIHR).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.